Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality

Objective To assess the prevalence of disease- and therapy-related complications and of the organ damage after a follow-up of 15 years or more in patients with primary antiphospholipid syndrome (PAPS). Methods Medical records of patients prospectively followed in our centre for at least 15 years wer...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2014-10, Vol.23 (12), p.1255-1258
Main Authors: Dall’Ara, F, Reggia, R, Taraborelli, M, Andreoli, L, Taglietti, M, Frassi, M, Franceschini, F, Tincani, A
Format: Article
Language:English
Subjects:
Adult
Aged
Antibodies
Anticoagulants
Antiphospholipid Syndrome - complications
Antiphospholipid Syndrome - mortality
Autoimmune diseases
Connective Tissue Diseases - etiology
Disease
Female
Humans
Immunology
Lupus
Male
Medical records
Middle Aged
Mortality
Obstetrics
Patients
Retrospective Studies
Sepsis
Serology
White people
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To assess the prevalence of disease- and therapy-related complications and of the organ damage after a follow-up of 15 years or more in patients with primary antiphospholipid syndrome (PAPS). Methods Medical records of patients prospectively followed in our centre for at least 15 years were retrospectively reviewed. Results Thirty-five Caucasian patients (33 female, two male) with diagnosis of PAPS followed from 1984 to 2013 with a mean age at onset of 32 years (SD 8.17) and a median follow-up of 20.5 years (range 15–30) were included. The occurrence of systemic autoimmune disease was observed in 14% of patients. Haemorrhagic, infective and neoplastic events were recorded in 34%, 6% and 9% respectively. Organ damage was present in 20% of patients at the end of the follow-up (17% neurological and 3% renal) and was significantly associated with the occurrence of thrombotic events (p: 0.027), particularly arterial (p 
ISSN:0961-2033
1477-0962
DOI:10.1177/0961203314534308